Table 2.

 Synopsis of correlations among different clinical subgroups of breast cancer patients

Parameter pair	Clinical subgroup	No. of patients	Spearman correlation	P‐value
COX‐2 versus HER‐2	All cases	47	0.575	<0.001
	−	28	0.626	<0.001
	ER−	13	0.681	0.009
	ER+	26	0.531	0.005
	PR−	12	0.815	<0.001
	PR+	25	0.560	0.004
	SBR I/II	23	0.547	0.007
	SBR III	23	0.660	<0.001
COX‐2 versus VEGF‐C	All cases	54	0.147	0.287
	ER−	15	0.534	0.037
HER‐2 versus VEGF‐C	All cases	46	0.176	0.241
	−	27	0.453	0.018
	ER−	13	0.675	0.010
	PR−	12	0.577	0.045
COX‐2 versus LVD	All cases	55	0.481	<0.001
	−	34	0.432	0.011
	+	21	0.557	0.009
	ER−	15	0.521	0.045
	PR+	25	0.574	0.003
	SBR I/II	27	0.575	0.002
	SBR III	27	0.384	0.047
HER‐2 versus LVD	All cases	47	0.128	0.390
VEGF‐C versus LVD	All cases	54	0.038	0.782
	SBR III	27	0.413	0.032
COX‐2 versus LVS	All cases	55	0.400	0.003
	−	34	0.574	<0.001
	ER+	26	0.564	0.003
	PR+	25	0.623	<0.001
	SBR I/II	27	0.554	0.003
HER‐2 versus LVS	All cases	47	0.124	0.405
	−	28	0.430	0.023
	SBR I/II	23	0.433	0.039

(−) Negative; (+) positive; COX‐2, cyclooxygenase‐2; ER, estrogen receptor; HER‐2, human epidermal growth factor receptor; LVD, lymphovascular density; LVS, lymphovascular space; PR, progesterone receptor; SBR, Scarff‐Bloom‐Richardson grade; VEGF‐C, vascular endothelial growth factor C.